Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
NCT00061178 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL
Last updated 2016-10-19
Summary
The purpose of this study is to determine whether rhuMAb VEGF (Bevacizumab) is safe and effective for the treatment of renal cell cancer when other treatments have failed.
Conditions
- Renal Cell Cancer
Interventions
- DRUG
-
rhuMAb VEGF (Bevacizumab)
Sponsors & Collaborators
-
Genentech, Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
NCT02330783 ·Status: UNKNOWN ·Phase: PHASE2
-
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00324870 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)
NCT00672178 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
NCT00378703 ·Status: COMPLETED ·Phase: PHASE2
-
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
NCT02724020 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
NCT00515697 ·Status: COMPLETED ·Phase: PHASE2
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
NCT06005818 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients
NCT00421512 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
NCT04489771 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
NCT02118337 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
NCT00077974 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
NCT00651482 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT04300140 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00112840 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
NCT05030506 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
NCT01664182 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study of 6MW3211 in Patients With Renal Cancer
NCT05440045 ·Status: UNKNOWN ·Phase: PHASE2
-
Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer
NCT00005045 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03141177 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
NCT04152018 ·Status: TERMINATED ·Phase: PHASE1
-
PS-341 in Treating Patients With Metastatic Kidney Cancer
NCT00025376 ·Status: COMPLETED ·Phase: PHASE2
-
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
NCT03092856 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
NCT04810078 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00684996 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
NCT03729245 ·Status: TERMINATED ·Phase: PHASE3